Insider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at $10,843,695.72. The trade was a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The stock was sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total value of $5,748,800.00.

United Therapeutics Trading Down 1.2%

Shares of United Therapeutics stock traded down $6.68 during trading hours on Friday, reaching $569.11. The stock had a trading volume of 318,251 shares, compared to its average volume of 480,686. The firm has a 50 day simple moving average of $556.50 and a two-hundred day simple moving average of $506.65. The firm has a market capitalization of $24.16 billion, a price-to-earnings ratio of 21.01, a P/E/G ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $6.63 earnings per share. Sell-side analysts forecast that United Therapeutics Corporation will post 27.64 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp raised its position in shares of United Therapeutics by 83.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 12,641 shares of the biotechnology company’s stock valued at $7,496,000 after purchasing an additional 5,764 shares in the last quarter. Lombard Odier Asset Management Switzerland SA acquired a new position in shares of United Therapeutics in the 1st quarter valued at approximately $388,000. Lombard Odier Asset Management USA Corp acquired a new position in shares of United Therapeutics in the 1st quarter valued at approximately $280,000. Public Employees Retirement System of Ohio raised its position in shares of United Therapeutics by 13.6% in the 1st quarter. Public Employees Retirement System of Ohio now owns 25,010 shares of the biotechnology company’s stock valued at $14,830,000 after purchasing an additional 3,003 shares in the last quarter. Finally, Atika Capital Management LLC acquired a new position in shares of United Therapeutics in the 1st quarter valued at approximately $7,323,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have weighed in on UTHR shares. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. TD Cowen upped their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. Article Title
• Neutral Sentiment: Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $660 price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of Moderate Buy and a target around $619.42, which may help support the stock. Article Title

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.